Security key
10806X102
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (BBIO)
CUSIP: 10806X102
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Total 13F shares
- 3,035,032
- Total 13F value
- $225,379,679
- Share change
- +43,362
- Put/Call ratio
- 45%
- SEC-reported price per share
- $74.48
- Number of holders
- 109
- Value change
- +$3,490,561
- Number of buys
- 63
- Number of sells
- 43
- Shares outstanding
- 195,328,418
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
109
Top holders
10
BBIO full security history
Ownership snapshot
Full 13F holder table
BridgeBio Pharma, Inc. SEC filings
BridgeBio Pharma, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
KKR Genetic Disorder L.P.
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 7%
13D/G row: KKR Genetic Disorder L.P.
Showing 1-6 of 15 holder rows.
Quick read
KKR Genetic Disorder L.P. leads the comparable SEC ownership view at 7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens KKR Genetic Disorder L.P.'s linked filing trail.
Comparable ownership
Top 5
KKR Genetic Disorder L.P.
7%
Janus Henderson Group Ltd.
6.8%
FARALLON CAPITAL MANAGEMENT, L.L.C.
5.5%
Farallon Capital Partners, L.P.
5.2%
BlackRock, Inc.
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. |
13D/G
3/4/5
10%+ Owner
|
7%
|
$476,864,517
13,260,971 shares
|
-$215,760,000 | 12 May 2025 |
| Janus Henderson Group Ltd. |
13F
13D/G
Company · JANUS HENDERSON GROUP PLC
|
6.8%
from 13D/G
|
$978,607,712
13,179,013 shares
|
— | 31 Mar 2026 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13D/G
13F
Company
|
5.5%
|
$836,992,038
10,743,063 shares
|
$0 | 30 Jun 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
5.2%
|
$674,408,855
10,226,063 shares
|
$0 | 22 May 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
from 13D/G
|
$1,073,758,277
16,296,054 shares
mixed-class rows
|
— | 31 Mar 2026 |
| Neil Kumar |
13D/G
3/4/5
Chief Executive Officer, Director
|
4.6%
|
$689,354,243
9,282,982 shares
|
-$87,903,790 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
109
Shares
3,035,032
Rows available
109
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
457
Q2 2026 holders
109
Holder diff
-348
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|